Business Context and Reporting Period
Company: Capsovision, Inc. (CV)
Filing Type: Form 10-Q (Unaudited)
Period Ended: June 30, 2026
Business Overview: Capsovision is a medical technology company developing capsule endoscopy solutions for gastrointestinal (GI) imaging. Its primary commercial product is the CapsoCam Plus for small bowel imaging. The company is currently developing the CapsoCam Colon for large intestine imaging and integrating AI capabilities into its platform. The company is classified as an Emerging Growth Company and a Smaller Reporting Company.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended June 30, 2026 |
Six Months Ended June 30, 2026 |
Six Months Ended June 30, 2025 |
|---|---|---|---|
| Net Revenue | $3,643 | $6,435 | $6,098 |
| Gross Profit | $1,871 | $3,200 | $3,305 |
| Gross Margin | 51% | 50% | 54% |
| Operating Loss | $(7,580) | $(14,673) | $(10,033) |
| Net Loss | $(7,481) | $(14,514) | $(10,000) |
| Cash and Cash Equivalents (End of Period) | $9,077 (as of June 30, 2026) | ||
| Net Cash Used in Operating Activities | $(14,469) (Six Months 2026) | ||
| Accumulated Deficit | $(170,179) (as of June 30, 2026) |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 10% year-over-year for the quarter and 6% for the six-month period. Growth was driven by a 13% increase in unit sales of CapsoCam Plus capsules, partially offset by a 3% decrease in average selling price due to competitive pressure. International sales grew 20% in the quarter.
- Margin Compression: Gross margin declined from 54% to 50% for the six-month period. This was attributed to competitive pricing pressures and increased customs and tariff expenses resulting from changes in U.S. trade policies.
- Expense Increases:
- R&D Expenses: Increased 57% (quarter) and 50% (six months) primarily due to ongoing clinical trials for CapsoCam Colon and non-recurring engineering services for a new CMOS image sensor development agreement with Canon Inc.
- G&A Expenses: Increased 80% (quarter) and 35% (six months) due to costs associated with operating as a public company (insurance, board compensation), new ERP implementation, and increased stock-based compensation.
- Capital Raise: In March 2026, the company completed a Private Placement, issuing approximately 2.87 million shares for gross proceeds of $14.0 million (net proceeds ~$13.4 million).
Guidance, Outlook, and Risks
- Going Concern: The filing explicitly states there is substantial doubt about the company's ability to continue as a going concern within one year. Management believes existing cash balances ($9.1 million) are insufficient to fund operations for the next 12 months without additional financing.
- Product Pipeline & Regulatory:
- CapsoCam Colon: The company abandoned the first-generation submission and is prioritizing a second-generation product with improved optics and AI. A pivotal study with 801 patients is complete; FDA 510(k) submission is expected in Q4 2026. Commercialization is not expected until mid-2027.
- AI Integration: FDA clearance for AI-assisted pathology detection in CapsoCam Plus is anticipated by Q3 2026. EU commercialization for this feature has already begun.
- Pancreatic Cancer: A study for early pancreatic cancer detection (CapsoCam UGI) is underway with 3 patients enrolled as of the filing date.
- Internal Controls: The company identified two material weaknesses in internal control over financial reporting (IT general controls and segregation of duties) as of June 30, 2026, which have not been fully remediated.
- Supply Chain Risks: Significant reliance on single-source suppliers in Asia (Taiwan and Japan) exposes the company to geopolitical risks, trade tariffs, and natural disasters.
Investor Verification Checklist
- Liquidity Runway: Verify the timeline and certainty of additional capital raising efforts given the "substantial doubt" going concern warning.
- Regulatory Milestones: Monitor the Q4 2026 FDA 510(k) submission for CapsoCam Colon and Q3 2026 clearance for AI-enhanced CapsoCam Plus.
- Margin Trends: Assess the impact of U.S. tariffs and competitive pricing on future gross margins.
- Internal Controls: Review progress on remediation of material weaknesses in financial reporting and IT controls.
- Customer Concentration: Note that one customer (Aureliance) represented 11% of revenue and 25% of accounts receivable in the six-month period.